Mabpharm (HKSE:02181) Other Long-Term Liabilities : HK$414.44 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Other Long-Term Liabilities?

Mabpharm's other long-term liabilities for the quarter that ended in Dec. 2023 was HK$414.44 Mil.

Mabpharm's quarterly other long-term liabilities increased from Dec. 2022 (HK$240.24 Mil) to Jun. 2023 (HK$283.05 Mil) and increased from Jun. 2023 (HK$283.05 Mil) to Dec. 2023 (HK$414.44 Mil).

Mabpharm's annual other long-term liabilities increased from Dec. 2021 (HK$32.46 Mil) to Dec. 2022 (HK$240.24 Mil) and increased from Dec. 2022 (HK$240.24 Mil) to Dec. 2023 (HK$414.44 Mil).

Mabpharm Other Long-Term Liabilities Historical Data

The historical data trend for Mabpharm's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Other Long-Term Liabilities Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial								-	-	-	-	-

Mabpharm Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Mabpharm Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Mabpharm's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines